ANI Pharmaceuticals vs Ipsen
ANI Pharmaceuticals vs Ipsen, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: ANI Pharmaceuticals is on 49/100 and Ipsen on 33/100.
Where each one leads
ANI Pharmaceuticals
- our overall score: 49/100 against 33/100
- headcount growth: +95.8% against +8.0%
Ipsen
- agent readiness: 45/100 against 31/100
- domain rating: 76/100 against 56/100
- headcount: 6,664 against 707
- LinkedIn following: 317,774 against 31,660
At a glance
| Measure | ANI Pharmaceuticals | Ipsen |
|---|---|---|
| What it is | Diversified biopharmaceutical company focused on rare diseases, generics, and established brands. | Global biopharmaceutical company focused on oncology, rare diseases, and neuroscience. |
| Category | Biotech, Pharmaceuticals, Rare Disease, Generics | Biotech, MedTech, HealthTech, Genomics |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Software | hardware | services | marketplace | platform |
| Founded | 1996 | 1929 |
| Headquarters | Baudette, United States | Paris, France |
| Status | Active | Active |
Size, funding and growth
| Measure | ANI Pharmaceuticals | Ipsen |
|---|---|---|
| Employees | 707 | 6,664 |
| Headcount growthLast 12 months | +95.8% | +8.0% |
| Open roles | Not published | 100 |
| Total funding | $671M | Not published |
| Latest round | Acquisition | Grant (prize money) |
| LinkedIn followers | 31,660 | 317,774 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | ANI Pharmaceuticals | Ipsen |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 49/100 | 33/100 |
| Traction | 60/100 | 20/100 |
| Team | 10/100 | 30/100 |
| Community | Not published | 8/100 |
| Search visibility | 23/100 | 39/100 |
| Quality | 58/100 | Not published |
| Agent readinessHow well an AI agent can read and act on the site | F (31/100) | D (45/100) |
| Domain ratingLink authority, 0-100 | 56/100 | 76/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | ANI Pharmaceuticals | Ipsen |
|---|---|---|
| Hosting | Self Managed | Self Managed |
| CMS | Not detected | WordPress |
| Frameworks | Jquery, Bootstrap | Tailwind CSS, Bootstrap |
| Analytics | Google Analytics 4 | Jetpack Stats |
ANI Pharmaceuticals vs Ipsen: common questions
Which is better, ANI Pharmaceuticals or Ipsen?
On our 0-100 score ANI Pharmaceuticals rates higher (49/100 against 33/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do ANI Pharmaceuticals and Ipsen compare on the numbers?
ANI Pharmaceuticals leads on our overall score (49/100 against 33/100), headcount growth (+95.8% against +8.0%). Ipsen leads on agent readiness (45/100 against 31/100), domain rating (76/100 against 56/100), headcount (6,664 against 707), LinkedIn following (317,774 against 31,660).
Read the full ANI Pharmaceuticals review and pricing or the Ipsen review and pricing. You can also browse other ANI Pharmaceuticals alternatives we track.